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Does It Take Two to Tango?*Christopher M. O’Connor, MD,y Tariq Ahmad, MD, MPHzThe cardiac retains salt and water because the
kidneys do not excrete sodium normally.
—Eugene Stead, Jr. (1)T he last century saw some of the giants inmedicine meticulously unearth key mecha-nisms of cardiorenal connections in heart
failure (HF); nonetheless, the precise role of the heart
and the kidney in the pathogenesis of HF continues to
elude clinicians. An untouched dictum, however, for
almost the past 100 years, has been the central impor-
tance of sodium in maintaining ﬂuid homeostasis and
progression of HF. In fact, the relevant chapter from
the 2015 edition of Heart Failure: A Companion to
Braunwald’s Heart Disease almost echoes a review of
this topic from 1948 (2,3). Chloride, on the other
hand, despite ﬂanking sodium as its anionic counter-
part in salt, has remained largely ignored, serving in
the medical literature and clinical practice as an after-
thought to the more popular electrolytes sodium or
potassium, or simply a substitute for bicarbonate to
preserve electroneutrality.SEE PAGE 659Confronting a century of accepted wisdom, this
issue of the Journal includes a provocative study by
Grodin et al. (4) who raise the question that chloride*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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educational grants from Thoratec Inc.might be just as, if not more, important than sodium
in the pathogenesis of acute decompensated HF
(ADHF). They retrospectively examined the prog-
nostic value of admission chloride in 2 distinctive
populations of patients with ADHF: 1,318 consecutive
patients with this diagnosis at the Cleveland Clinic
from 2008 to 2013 (discovery cohort), and 876 pa-
tients from the University of Pennsylvania from 2004
to 2009 (validation cohort). Mortality was deter-
mined using the electronic medical record and Social
Security Death Index. The principal ﬁnding was
that chloride levels were associated with increased
risk of death, even after adjusting for age, sodium,
blood urea nitrogen, length of stay, ischemic cause of
HF, beta-blocker use, renin-angiotensin system in-
hibitor use, and mineralocorticoid antagonist use.
The association of admission sodium with mortality
vanished after multivariable adjustments included
chloride.
As simply another manuscript examining the
prognostic value of a biomarker in HF, this paper has
some room for improvement (5). The cohorts
included are not representative of the overall pop-
ulation of patients with ADHF (6). There does not
seem to be any speciﬁc phenotype of the HF syn-
drome represented; in fact, the inclusion criteria do
not even include ejection fraction cutpoints, and
there are substantial differences between the
Cleveland Clinic and University of Pennsylvania co-
horts. It has long been realized that HF is likely a
syndrome of multiple subdiseases; yet, this analysis
disregards any attempts to include a more homoge-
nous population of patients (7).
Nor did the authors adjust for well-deﬁned
markers of prognosis in ADHF (8). Prior models have
included physical ﬁndings, such as low systolic blood
pressure, high heart rate, evidence of congestion;
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668comorbidities, such as atrial ﬁbrillation, diabetes,
cerebrovascular disease, depression; and additional
markers, such as serum creatinine and bicarbonate.
Furthermore, they do not adjust for natriuretic pep-
tide levels, a class 1A indication for prognostication
of HF and a sine qua non for any contemporary
biomarker study. The discriminatory statistic, area
under the receiver-operating characteristic curve
(AUC), often referred to as the C statistic, is only re-
ported for the discovery cohort and is almost as low as
a coin ﬂip for both sodium and chloride (0.56 and 0.60,
respectively). Furthermore, no signiﬁcant increase
occurs when chloride levels are added to the multi-
variate prediction model (0.68 vs. 0.69). Finally,
although the authors note signiﬁcant improvements in
reclassiﬁcation metrics (net reclassiﬁcation improve-
ment and integrated discrimination improvement),
the prognostic implications of these results are
ambiguous in the absence of either a validated risk
model or clearly deﬁned categories of risk (5). On the
basis of these issues, much work needs to be done
before chloride is used for the purposes of risk pre-
diction in ADHF.
If, however, we consider the potential mechanistic
underpinnings of these ﬁndings, we are confronted
with a possibility that could usher in a paradigm shift
in the basic understanding of HF pathophysiology—
perhaps chloride plays a fundamental role in disease
progression. Certainly, ample data exist to suggest
that our current understanding of ADHF does not
adequately explain clinical observations and nu-
merous clinical trial results. Despite repeated associ-
ations of serum sodium with morbidity and mortality
in patients with HF, pharmacological therapies, such
as vasopressin antagonists that target serum sodium
levels, have not improved patient outcomes (9). Other
important markers of prognosis, such as blood urea
nitrogen, creatinine, natriuretic peptides, invasive
hemodynamics, left ventricular ejection fraction, and
myocardial viability testing, have also failed to
translate into successful therapeutic interventions,
leading to an impasse in the development of effective
ADHF treatments (10).
On the other hand, chloride has accumulated an
impressive body of science supporting a central role
in the pathogenesis of heart disease that challenges
its presumed ancillary role in maintaining electrolyte
homeostasis. The most important extracellular anion
in the human body, chloride serves many bodily
functions, including maintenance of osmotic pres-
sure, acid–base balance, and muscular activity and
movement of water between ﬂuid compartments
(11). Chloride channels are evolutionarily conserved
across eukaryotes, conﬁrming their primacy in themost essential of cellular functions. A broad spectrum
of mendelian disorders involving several organ sys-
tems, ranging from cystic ﬁbrosis to epilepsy, are
caused by mutations in chloride channels. In partic-
ular, several rare diseases characterized by electrolyte
and hemodynamic dysregulation, such as Bartter and
Gitelman syndromes, result from mutations in these
channels (12). The recent discovery of a family of
chloride-sensitive WNK (With No lysine ¼ K) kinases
as central orchestrators of numerous ion-transport
and neurohormonal pathways in response to phy-
siological perturbations demonstrates an enticing
potential link between hypochloremia and HF path-
ogenesis (13). Importantly, WNK kinases have been
shown to regulate the targets of both loop and thia-
zide diuretics (14). Furthermore, a genome-wide
association study implicated common variation in
the CLCNKA gene as playing a role in increasing risk
of HF—this gene encodes the renal CLCNKA chloride
channel, providing further evidence for the signiﬁ-
cance of chloride in the cardiorenal axis (15).
Where should we go from here? The ﬁndings
presented surely represent the fountainhead of
more conclusive investigations of chloride’s role in
HF: as of today, only 21 articles in PubMed have the
words “chloride” and “heart failure” in their title.
The next step is to re-examine the association of
chloride with clinical outcomes in prior HF trials and
databases. If these results are validated, it would
justify pilot human studies aimed at targeting
hypochloremia by modifying current therapies,
attempting chloride repletion, and applying novel
therapeutics that use the growing understanding of
chloride pathobiology.
In this modern era of investigations into HF patho-
genesis, much expectation has rested on the shoulders
of complex technologies, such as microRNA proﬁling,
genomics, proteomics, and systems biology, to ﬁll in
substantial gaps in knowledge (16). The authors of this
paper should be commended for successfully revisit-
ing a ubiquitous, yet ignored, electrolyte that com-
prises the “basic metabolic panel.” These results
suggest that an important clue to improving the un-
derstanding of HF was present all along—as sodium’s
partner in salt. Thus, whereas a century of investiga-
tion continues to demonstrate that sodium chloride
is important in the pathogenesis of HF, what was
missing was the realization that it takes two to tango.
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